Tramadol intravenous - Revogenex/Avenue Therapeutics

Drug Profile

Tramadol intravenous - Revogenex/Avenue Therapeutics

Alternative Names: RVX 109; Tramadol hydrochloride - Revogenex/Avenue Therapeutics

Latest Information Update: 09 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Revogenex
  • Developer Avenue Therapeutics
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative pain

Most Recent Events

  • 08 Sep 2017 Phase II development in Postoperative pain is ongoing in USA
  • 19 May 2017 Avenue Therapeutics receives Notice of allowance for Intravenous tramadol in USA
  • 16 Mar 2017 Avenue plans three phase III clinical trials (In an orthopaedic model, In a soft tissue model, An open-label safety study) for Postoperative pain in USA in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top